View Filing Data

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2016	Nov. 11, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3
Trading Symbol	ETRM
Entity Registrant Name	EnteroMedics Inc
Entity Central Index Key	0001371217
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		113,154,501

Consolidated Balance Sheets - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 6,841,547	$ 7,927,240
Accounts receivable	191,680	57,928
Inventory	2,133,861	1,686,324
Prepaid expenses and other current assets	371,386	831,495
Total current assets	9,538,474	10,502,987
Property and equipment, net	228,459	326,296
Other assets	809,390	757,802
Total assets	10,576,323	11,587,085
Current liabilities:
Current portion of convertible notes payable	4,439,133	717,391
Accounts payable	680,819	172,050
Accrued expenses	2,851,383	3,595,415
Accrued interest payable		1,172
Total current liabilities	7,971,335	4,486,028
Convertible notes payable, less current portion (net of discounts of $217,306 and $149,340 at September 30, 2016 and December 31, 2015, respectively)	1,236,867	549,791
Common stock warrant liability	212,915	2,877,817
Total liabilities	9,421,117	7,913,636
Commitments and contingencies (note 5)
Stockholders' equity:
Common stock, $0.01 par value; 150,000,000 and 13,333,333 shares authorized at September 30, 2016 and December 31, 2015, respectively; 74,414,549 and 7,163,820 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively	744,145	71,638
Additional paid-in capital	296,917,990	281,182,349
Accumulated deficit	(296,506,929)	(277,580,538)
Total stockholders' equity	1,155,206	3,673,449
Total liabilities and stockholders' equity	$ 10,576,323	$ 11,587,085

Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Convertible notes payable, less current portion, discounts	$ 217,306	$ 149,340
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	150,000,000	13,333,333
Common stock, shares issued	74,414,549	7,163,820
Common stock, shares outstanding	74,414,549	7,163,820

Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
Consolidated Statements of Operations - USD ($)	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Sales	$ 296,760	$ 64,000	$ 644,760	$ 143,000
Cost of goods sold	146,631	23,346	342,070	54,109
Gross profit	150,129	40,654	302,690	88,891
Operating expenses:
Selling, general and administrative	3,361,572	4,289,017	15,088,297	13,952,899
Research and development	1,253,390	1,762,013	3,879,378	6,451,406
Total operating expenses	4,614,962	6,051,030	18,967,675	20,404,305
Operating loss	(4,464,833)	(6,010,376)	(18,664,985)	(20,315,414)
Other income (expense):
Interest income	1,493	157	4,991	1,446
Interest expense	(1,391,134)	(565,522)	(3,393,374)	(840,491)
Change in value of warrant liability	241,741	2,416,443	3,330,254	2,416,443
Change in value of convertible notes payable	(909,030)		(200,004)
Other, net	(700)	8,628	(3,272)	9,561
Net loss	$ (6,522,463)	$ (4,150,670)	$ (18,926,390)	$ (18,728,455)
Net loss per share-basic and diluted	$ (0.17)	$ (0.60)	$ (0.99)	$ (3.35)
Shares used to compute basic and diluted net loss per share	38,781,980	6,931,306	19,162,561	5,587,847

Consolidated Statements of Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
Consolidated Statements of Comprehensive Loss - USD ($)	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Net loss	$ (6,522,463)	$ (4,150,670)	$ (18,926,390)	$ (18,728,455)
Comprehensive loss	$ (6,522,463)	$ (4,150,670)	$ (18,926,390)	$ (18,728,455)

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net loss	$ (18,926,390)	$ (18,728,455)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	109,382	146,292
Loss on sale of equipment		885
Stock-based compensation	2,201,949	4,357,742
Amortization of commitment fees, debt issuance costs and original issue discount	1,596,093	754,242
Change in value of convertible notes payable	200,004
Change in value of warrant liability	(3,330,254)	(2,416,443)
Change in operating assets and liabilities:
Accounts receivable	(133,752)	(22,300)
Inventory	(447,537)	(395,504)
Prepaid expenses and other current assets	459,970	189,097
Other assets	(290,480)	(66,643)
Accounts payable	508,769	(198,864)
Accrued expenses	(744,036)	(346,245)
Accrued interest payable	1,673,793	(514,937)
Net cash used in operating activities	(17,122,489)	(17,241,133)
Cash flows from investing activities:
Purchases of property and equipment	(11,544)	(37,263)
Net cash used in investing activities	(11,544)	(37,263)
Cash flows from financing activities:
Proceeds from sale of common stock and warrants for purchase of common stock		22,651,932
Common stock financing costs	(28,000)	(1,731,714)
Proceeds from convertible notes payable	17,250,000
Repayments on convertible notes payable	(446,867)
Repayments on notes payable		(3,000,000)
Debt issuance costs	(726,793)
Net cash provided by financing activities	16,048,340	17,920,218
Net increase (decrease) in cash and cash equivalents	(1,085,693)	641,822
Cash and cash equivalents:
Beginning of period	7,927,240	11,619,167
End of period	6,841,547	12,260,989
Supplemental disclosure:
Cash paid for interest	169,259	$ 601,185
Noncash investing and financing activities:
Conversion of convertible notes and interest payable	$ 14,234,201

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2016

Summary of Significant Accounting Policies

(1) Summary of Significant Accounting Policies

Description of Business

EnteroMedics Inc. (the Company) develops and sells implantable systems to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company was incorporated in the state of Minnesota on December 19, 2002 and was reincorporated in Delaware on July 22, 2004. The Company is headquartered in St. Paul, Minnesota. In January 2006, the Company established EnteroMedics Europe Sárl, a wholly-owned subsidiary located in Switzerland.

The Company’s board of directors and stockholders approved a 1-for-15 reverse split (the Reverse Stock Split) of the Company’s outstanding common stock that became effective after trading on January 6, 2016. The Reverse Stock Split did not change the par value of the Company’s stock or the number of preferred shares authorized by the Company’s Fifth Amended and Restated Certificate of Incorporation. An amendment to the Certificate of Incorporation was also approved in connection with the Reverse Stock Split to increase the number of shares of the Company’s common stock authorized for issuance to 150 million shares, effective immediately after the Reverse Stock Split on January 6, 2016. All share and per share amounts have been retroactively adjusted to reflect the Reverse Stock Split for all periods presented.

Risks and Uncertainties

The Company is focused on the design and development of medical devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders and currently has approvals to commercially launch the vBloc Rechargeable System in the United States, the European Economic Area and other countries that recognize the European CE Mark. The Company has devoted substantially all of its resources to recruiting personnel, developing its product technology, obtaining patents to protect its intellectual property and raising capital, and has recently commenced commercial operations in the United States deriving revenues from its primary business activity in 2015.

The Company’s products require approval from the U.S. Food and Drug Administration (FDA) or corresponding foreign regulatory agencies prior to commercial sales. The Company received FDA approval on January 14, 2015 for vBloc Therapy, delivered via the vBloc Rechargeable System, and has begun a controlled commercial launch at select surgical centers in the United States. The vBloc Rechargeable System has also received CE Mark and was previously listed on the Australian Register of Therapeutic Goods (ARTG).

The medical device industry is characterized by frequent and extensive litigation and administrative proceedings over patent and other intellectual property rights. Whether a product infringes a patent involves complex legal and factual issues, the determination of which is often difficult to predict, and the outcome may be uncertain until the court has entered final judgment and all appeals are exhausted. The Company’s competitors may assert that its products or the use of the Company’s products are covered by U.S. or foreign patents held by them.

The Company’s activities are subject to significant risks and uncertainties, including the ability to obtain additional financing, and there can be no assurance that the Company will be successful in obtaining additional financing on favorable terms, or at all. If adequate funds are not available, the Company may have to further reduce its cost structure until financing is obtained and/or delay development or commercialization of products or license to third parties the rights to commercialize products or technologies that the Company would otherwise seek to commercialize.

Basis of Presentation

The Company has prepared the accompanying condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America. The Company’s fiscal year ends on December 31.

The accompanying condensed consolidated financial statements and notes thereto are unaudited. In the opinion of the Company’s management, these statements include all adjustments, which are of a normal recurring nature, necessary to present a fair presentation. Interim results are not necessarily indicative of results for a full year. The condensed consolidated balance sheet as of December 31, 2015 was derived from audited consolidated financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America. The information included in this Form 10-Q should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2015.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Principles of Consolidation

The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany transactions and accounts have been eliminated in consolidation.

Fair Value of Financial Instruments

Carrying amounts of certain of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their short maturities. The Company’s common stock warrants are required to be reported at fair value and the Company has elected to report its senior amortizing convertible notes at fair value. The fair values of common stock warrants and investments in debt and equity securities, if any, are disclosed in Note 3. The fair value of the Company’s senior amortizing convertible notes is disclosed in Notes 3 and 7.

Common Stock Warrant Liability

Common stock warrants that were issued in connection with the July 8, 2015 public offering and the November 9, 2015, January 11, 2016 and May 2, 2016 senior amortizing convertible notes are classified as a liability in the condensed consolidated balance sheets, as the common stock warrants issued provide for certain anti-dilution protections in the event shares of common stock or securities convertible into shares of common stock are issued below the then-existing exercise price. The fair value of these common stock warrants is re-measured at each financial reporting period and immediately before exercise, with any changes in fair value being recognized as a component of other income (expense) in the condensed consolidated statements of operations.

Cash and Cash Equivalents

The Company considers highly liquid investments generally with maturities of 90 days or less when purchased to be cash equivalents. Cash equivalents are stated at cost, which approximates market value. The Company’s cash equivalents are primarily in money market funds and certificates of deposit. The Company deposits its cash and cash equivalents in high-quality credit institutions.

Short-Term Investments

The Company considers all investments with maturities greater than three months and less than one year at the time of purchase as short-term investments and classifies them as either available for sale or held to maturity. The Company also considers certain investments with maturities greater than one year but which are also held for liquidity purposes and are available for sale as short-term investments.

Available-for-sale securities are carried at fair value based on quoted market prices, with the unrealized gains and losses included in other comprehensive income within stockholders’ equity in the condensed consolidated balance sheets. Realized gains and losses and declines in value judged to be other than temporary on available-for-sale securities are included in interest and other income. Interest and dividends on securities classified as available for sale are included in interest income. The cost of securities sold is based on the specific identification method.

Short-term investments in debt securities which the Company has the positive intent and ability to hold to maturity are reported at cost, adjusted for premiums and discounts that are recognized in interest income, using the interest method, over the period to maturity. Unrealized losses on held-to-maturity securities reflecting a decline in value determined to be other than temporary are charged to income.

Inventory

The Company accounts for inventory at the lower of cost or market and records any long-term inventory as other assets in the condensed consolidated balance sheets.

Property and Equipment, Net

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over their estimated useful lives of five to seven years for furniture and equipment and three to five years for computer hardware and software. Leasehold improvements are amortized on a straight-line basis over the lesser of their useful life or the term of the lease. Upon retirement or sale, the cost and related accumulated depreciation or amortization are removed from the condensed consolidated balance sheets and the resulting gain or loss is reflected in the condensed consolidated statements of operations. Repairs and maintenance are expensed as incurred.

Impairment of Long-Lived Assets

The Company evaluates its long-lived assets for impairment by comparison of the carrying amounts to future net undiscounted cash flows expected to be generated by such assets when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Should an impairment exist, the impairment loss would be measured based on the excess carrying value of the asset over the asset’s fair value or estimates of future discounted cash flows. The Company has not identified any such impairment losses to date.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance for deferred income tax assets is recorded when it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The Company has provided a full valuation allowance against the gross deferred tax assets. The Company’s policy is to classify interest and penalties related to income taxes as income tax expense in the condensed consolidated statements of operations.

Medical Device Excise Tax

On January 14, 2015, the Company received FDA approval for vBloc Therapy, delivered via the vBloc Rechargeable System, and starting in the second quarter of 2015 revenues were generated from sales in the United States. As a result, the Company is now required to pay a quarterly Medical Device Tax which is a part of the Affordable Care Act, which imposes a 2.3% excise tax on the sale of certain medical devices by device manufactures, producers or importers. The excise tax was effective on sales of devices made after December 31, 2012. The Company records the Medical Device Tax as an operating expense in the condensed consolidated statements of operations. A moratorium was placed on the Medical Device Tax for 2016 and 2017.

Comprehensive Loss

Comprehensive loss is defined as the change in equity of a company during a period from transactions and other events and circumstances excluding transactions resulting from investment owners and distributions to owners. There was no difference from reported net loss for the three and nine months ended September 30, 2016 and 2015.

Revenue Recognition

Revenue is recognized when persuasive evidence of an arrangement exists, title or risk of loss has passed, the selling price is fixed or determinable and collection is reasonably assured. Products are sold through direct sales or medical device distributors and revenue is recognized upon sale to a bariatric center of excellence or a medical device distributor when no right of return or price protection exists. Terms of sales to international distributors are generally EXW, reflecting that goods are shipped “ex works,” in which risk of loss is assumed by the distributor at the shipping point. A provision for returns is recorded only if product sales provide for a right of return. No provision for returns was recorded for the three and nine months ended September 30, 2016 and 2015, as the product sales recorded did not provide for rights of return.

Research and Development Expenses

Research and development expenses are charged to expense as incurred. Research and development expenses include, but are not limited to, product development, clinical trial expenses, including supplies, devices, explants and revisions, quality assurance, regulatory expenses, payroll and other personnel expenses, materials and consulting costs.

Net Loss Per Share

Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is based on the weighted-average common shares outstanding during the period plus dilutive potential common shares calculated using the treasury stock method. Such potentially dilutive shares are excluded when the effect would be to reduce a net loss per share. The Company’s potential dilutive shares, which include outstanding common stock options and warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.

The following table sets forth the computation of basic and diluted net loss per share for the three and nine months ended September 30, 2016 and 2015:


	Three months ended September 30,						Nine months ended September 30,
	2016			2015			2016			2015
Numerator:
Net loss	$	(6,522,463	)	$	(4,150,670	)	$	(18,926,390	)	$	(18,728,455	)

Denominator for basic and diluted net loss per share:
Weighted-average common shares outstanding		38,781,980			6,931,306			19,162,561			5,587,847

Net loss per share—basic and diluted	$	(0.17	)	$	(0.60	)	$	(0.99	)	$	(3.35	)

The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented:


	September 30,
	2016		2015
Stock options outstanding		1,414,918		1,030,033
Warrants to purchase common stock		3,953,413		3,746,647

Recently Issued or Adopted Accounting Standards

In March 2016, the Financial Accounting Standards Board (FASB) issued Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (Accounting Standards Update No. 2016-09 (ASU 2016-09)). ASU 2016-09 modifies several aspects of the accounting for share-based payment awards, including income tax consequences, and classification on the statement of cash flows. This guidance will be effective for interim and annual reporting periods beginning after December 15, 2016. The Company is currently evaluating the impact of adopting ASU 2016-09 on its consolidated financial statements.

In May 2014, FASB issued Revenue from Contracts with Customers, Topic 606 (Accounting Standards Update No. 2014-09 (ASU 2014-09)), which provides a framework for the recognition of revenue, with the objective that recognized revenues properly reflect amounts an entity is entitled to receive in exchange for goods and services. This guidance will be effective for interim and annual reporting periods beginning after December 15, 2017. The Company is currently evaluating the impact of adopting ASU 2014-09 on its consolidated financial statements.

There have been no other significant changes in recent accounting pronouncements during the nine months ended September 30, 2016 as compared to the recent accounting pronouncements described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015.

Liquidity and Management's Plans

9 Months Ended

Sep. 30, 2016

Liquidity and Management's Plans

(2) Liquidity and Management’s Plans

The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has financed its operations to date principally through the sale of equity securities, debt financing and interest earned on investments. As of September 30, 2016, the Company had $6.8 million of cash and cash equivalents to fund its operations through 2016 and early 2017.

The Company’s operations include plans that consider the controlled commercial launch of vBloc Therapy, delivered via the vBloc Rechargeable System, which was approved by the FDA on January 14, 2015. The Company believes that it has the ability to manage the growth of its expenditures and operations depending on the amount of available cash flows. However, the Company will ultimately need to achieve sufficient revenues from product sales and/or obtain additional debt or equity financing to support its operations.

On November 4, 2015, the Company entered into a securities purchase agreement (the Purchase Agreement) with institutional investors to issue $25.0 million of senior amortizing convertible notes (the Notes) along with the accompanying warrants. $1.5 million of the Notes was funded at the first closing on November 9, 2015 (the First Closing). An additional $11.0 million of the Notes was funded at the second closing on January 11, 2016 (the Second Closing). Pursuant to two amendments to the Purchase Agreement entered into on May 2, 2016 (the First Amendment), and July 14, 2016 (the Second Amendment), $6.25 million was funded at the third closing on May 2, 2016 (The Third Closing). The remaining amount, up to $6.25 million, may be funded at the fourth closing, which can occur no later than December 1, 2016 (the Fourth Closing). In order for the Fourth Closing to occur, the holders of the Notes must waive certain conditions which are not currently satisfied due to recent declines in the Company’s stock price. Such waivers have not yet been either requested or provided. These conditions include (i) the requirement that the average VWAP of the Company’s stock price over the prior fifteen days be at least $0.20 per share, (ii) that the Company’s stock have an aggregate average daily dollar trading volume of more than $100,000 over prior fifteen days, and (ii) that the Company have an adequate number of common shares available for conversions of principal and interest related to the Fourth Closing on the date of the Fourth Closing (collectively, the Closing Conditions) (see also Note 6).

In May 2016, the Company received written notices from the Nasdaq Stock Market Nasdaq stating that the Company was not in compliance with the following two Nasdaq listing requirements: (1) the requirement that the Company have a minimum of $2.5 million stockholders’ equity (the Stockholders’ Equity Requirement) and (2) the $1.00 minimum bid price stock price requirement (the Minimum Bid Requirement).

On July 19, 2016, the Company received a letter from Nasdaq granting the Company an extension until November 14, 2016 to regain compliance with the Stockholders’ Equity Requirement. The extension was granted based on the plan the Company submitted to Nasdaq to regain compliance with the Stockholders’ Equity Requirement through a combination of note conversions and accelerated principal amortizations and infusions of equity capital prior to the deadline. We received a notice of delisting on November 9, 2016, and intend to appeal to Nasdaq for a hearing before the Listing Qualification Panel prior to being delisted. The basis for the Company’s appeal of the Nasdaq delisting notices is expected to consist of:

•

Fourth quarter 2016 reductions in the Company’s operating expense levels

•

On November 7, 2016, the Company filed a preliminary proxy statement for a special meeting of our stockholders in order to obtain approval for, among other things, an increase in the number of common shares authorized to be issued and the authorization to effect a reverse-split of its common stock. While obtaining shareholder approval of each of these proposals is not certain, the Company believes it will be able to obtain stockholder approval for the authorized share increase and reverse stock split in December 2016.

•

After stockholder approval is obtained, the Company intends to declare a reverse-split of its outstanding shares of common stock in such a ratio to increase its minimum bid stock price above the $1.00 minimum required by Nasdaq while maintaining its current authorized share count,

•

After stockholder approval is obtained to increase the number of authorized shares and the reverse stock split is implemented, the Company intends to conduct a firm commitment underwritten public offering consisting of common stock and warrants to purchase common stock in amounts sufficient to increase the Company’s shareholder equity above the $2.5 million Nasdaq minimum and to provide funding for the Company’s operations for the foreseeable future. The Company has not yet obtained any commitments to participate in the offering and does not expect to obtain any commitments until after the stockholder meeting has occurred.

Failure of the Company to receive shareholder approval in December 2016 on the proposals to increase the number of authorized shares and the authorization of a reverse stock split will likely result in Nasdaq delisting and will significantly impair the Company’s ability to raise the additional capital necessary to continue operations beyond the first quarter of 2017.

Short-term Investments and Fair Value Measurements

9 Months Ended

Sep. 30, 2016

Short-term Investments and Fair Value Measurements

(3) Short-term Investments and Fair Value Measurements

Fair value of financial assets and liabilities is defined as the price that would be received to sell an asset or transfer a liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy has been established that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below:

•

Level 1—Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

•

Level 2—Quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or model-derived valuations for which all significant inputs are observable, either directly or indirectly.

•

Level 3—Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable.

The Company’s assets that are measured at fair value on a recurring basis are classified within Level 1 or Level 2 of the fair value hierarchy. The Company does not hold any assets that are measured at fair value using Level 3 inputs. The types of instruments the Company invests in that are valued based on quoted market prices in active markets may include U.S. treasury securities and money market funds. Such instruments are classified by the company within Level 1 of the fair value hierarchy. U.S. treasuries are valued using unadjusted quoted prices for identical assets in active markets that the Company can access.

The types of instruments the Company invests in that are valued based on quoted prices in less active markets, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency include the Company’s U.S. agency securities, commercial paper, U.S. corporate bonds and municipal obligations. Such instruments are classified by the Company within Level 2 of the fair value hierarchy. The Company values these types of assets using consensus pricing or a weighted average price, which is based on multiple pricing sources received from a variety of industry standard data providers (e.g. Bloomberg), security master files from large financial institutions, and other third-party sources. The multiple prices obtained are then used as inputs into a distribution-curve-based algorithm to determine the daily market price.

The Company did not hold any short-term investments classified as available for sale or held to maturity as of September 30, 2016 and December 31, 2015.

The fair value of the Company’s common stock warrant liability is calculated using a Black-Scholes valuation model and is classified as Level 2 in the fair value hierarchy. The common stock warrants issued July 8, 2015 had a fair value of $172,981 and $2,759,583 on September 30, 2016 and December 31, 2015, respectively. The common stock warrants issued November 9, 2015 had a fair value of $14,488 and $118,234 on September 30, 2016 and December 31, 2015, respectively. The common stock warrants issued January 11, 2016 had a fair value of $15,610 and $515,157 on September 30, 2016 and January 11, 2016, respectively. The common stock warrants issued May 2, 2016 had a fair value of $9,836 and $150,195 on September 30, 2016 and May 2, 2016, respectively. The fair value was calculated using the following assumptions:


	July 2015 Warrants						November 2015 Warrants
	September 30, 2016			December 31, 2015			September 30, 2015			December 31, 2015
Risk-free interest rates		0.88	%		1.31	%		1.14	%		1.76	%
Expected life		27 months			36 months			49 months			58 months
Expected dividends		0	%		0	%		0	%		0	%
Expected volatility		97.89	%		97.94	%		96.40	%		86.27	%

	January 2016 Warrants						May 2016 Warrants
	September 30, 2016			January 11, 2016			September 30, 2016			May 2, 2016
Risk-free interest rates		1.14	%		1.58	%		1.14	%		1.32	%
Expected life		51 months			60 months			55 months			60 months
Expected dividends		0	%		0	%		0	%		0	%
Expected volatility		96.12	%		85.90	%		94.95	%		89.28	%

The following table summarizes fair value measurements of the Notes and the common stock warrants issued in 2015 and during the nine months ended September 30, 2016 by level at September 30, 2016:


	Level 1	Level 2		Level 3		Total
Senior amortizing convertible notes				$	5,676,000	$	5,676,000
Common stock warrants		$	212,915				212,915

Total		$	212,915	$	5,676,000	$	5,888,915

Through September 30, 2016, the Company had converted $3.2 million of the Notes’ principal and interest into shares of common stock. For the three month and nine month periods ended September 30, 2016, respectively, there were losses of $909,000 and $200,000 recognized in the condensed consolidated statements of operations from changes in fair value of the Notes.

During the three months ended September 30, 2016, all remaining amounts outstanding from the First Closing were paid off via conversions into shares of common stock. As of December 31, 2015, the fair value of the outstanding Notes from the First Closing was determined to be $1.3 million. On September 30, 2016 and January 11, 2016, the fair value of the outstanding Notes from the Second Closing was determined to be $2.4 million and $9.9 million, respectively. On September 30, 2016 and May 2, 2016, the fair value of the outstanding Notes from the Third Closing was determined to be $3.2 million and $6.0 million, respectively. The fair values were calculated using a Binomial Lattice model and the following assumptions:


	November 2015 Notes					January 2016 Notes
	September 30, 2016		December 31, 2015			September 30, 2016			January 11, 2016
Risk-free interest rates		N/A		1.11	%		0.65	%		1.01	%
Expected life		N/A		1.86 years			1.11 years			1.83 years
Expected dividends		N/A		0	%		0	%		0	%
Expected volatility		N/A		57.5	%		70.0	%		60.0	%
Fair value per share of common stock		N/A	$	1.95		$	0.14		$	1.33


	May 2016 Notes
	September 30, 2016			May 2, 2016
Risk-free interest rates		0.65	%		0.69	%
Expected life		1.11 years			1.52 years
Expected dividends		0	%		0	%
Expected volatility		70.0	%		65.0	%
Fair value per share of common stock	$	0.14		$	0.80

Inventory

9 Months Ended

Sep. 30, 2016

Inventory

(4) Inventory

From the Company’s inception, inventory related purchases had been used for research and development related activities and had accordingly been expensed as incurred. In December 2011, the Company began receiving ARTG listings for components of the Maestro Rechargeable System from the Australian Therapeutic Goods Administration, with the final components being listed on the ARTG in January 2012. As a result, the Company determined certain assets were recoverable as inventory beginning in December 2011. The Company accounts for inventory at the lower of cost or market and records any long-term inventory as other assets in the condensed consolidated balance sheets. There was approximately $686,000 and $519,000 of long-term inventory, primarily consisting of raw materials, as of September 30, 2016 and December 31, 2015, respectively.

Current inventory consists of the following as of:


	September 30, 2016		December 31, 2015
Raw materials	$	686,629	$	576,898
Work-in-process		1,431,056		1,066,345
Finished goods		16,176		43,081

Inventory	$	2,133,861	$	1,686,324

Commitments and Contingencies

9 Months Ended

Sep. 30, 2016

Commitments and Contingencies

(5) Commitments and Contingencies

Operating Lease

The Company rents its office, warehouse and laboratory facilities under an operating lease, which was originally set to expire on September 30, 2015. On August 25, 2015, the Company entered into an amendment extending the term of the operating lease for three years until September 30, 2018, with monthly base rent ranging from $18,925 to $20,345. Total rent expense recognized for each of the three month periods ended September 30, 2016 and 2015 was $58,905 and $67,718, and for each of the nine month periods ended September 30, 2016 and 2015 was $176,175 and $203,154. At September 30, 2016, future minimum payments under the lease are as follows:


Year ending December 31:
Remaining three months in 2016	$	58,905
2017		235,620
2018		176,715

	$	471,240

Product Liability Claims

The Company is exposed to product liability claims that are inherent in the testing, production, marketing and sale of medical devices. Management believes any losses that may occur from these matters are adequately covered by insurance, and the ultimate outcome of these matters will not have a material effect on the Company’s financial position or results of operations. The Company is not currently a party to any litigation and is not aware of any pending or threatened litigation that could have a material adverse effect on the Company’s business, operating results or financial condition.

Clinical Trials

The Company is evaluating the vBloc System in human clinical trials, including the EMPOWER trial and ReCharge trial. Both of these clinical trials require patients to be followed out to 60 months. The Company is required to pay for patient follow up visits only to the extent they occur. In the event a patient does not attend a follow up visit, the Company has no financial obligation. The Company is also required to pay for explants or revisions, including potential conversions of ReCharge control devices to active devices, should a patient request or be required to have one during the course of the clinical trials. The Company has no financial obligation unless an explant, revision or conversion is requested or required. Clinical trial costs are expensed as incurred.

Senior Amortizing Convertible Notes

9 Months Ended

Sep. 30, 2016

Senior Amortizing Convertible Notes

(6) Senior Amortizing Convertible Notes

On November 4, 2015, the Company entered into the Purchase Agreement to issue and sell to four institutional investors 7% senior amortizing convertible notes due 2017 in three separate closings. The Notes were initially convertible into shares of the Company’s common stock at a price equal to $4.35 per share with an aggregate principal amount of $25.0 million. Each Note was sold with a warrant to purchase a share of common stock (the Warrants) with an exercise price of $4.65 per share. The Company issued and sold Notes and Warrants for aggregate total proceeds of $12.5 million in two separate closings through March 31, 2016, and after entering into the First Amendment, which provided that the scheduled third closing would be split into two separate closings, issued and sold Notes and Warrants for aggregate total proceeds of $6.25 million in the Third Closing. The Company may issue and sell Notes and Warrants for aggregate total proceeds of up to $6.25 million in the Fourth Closing, which pursuant to the Second Amendment, is scheduled to occur no later than December 1, 2016. The Second Amendment provided the holders’ consent to the Company reducing the conversion price of the Notes from time to time in order to incentivize the holders of the Notes to convert their Notes into shares of the Company’s common stock. Since entering into the Second Amendment, we have experienced a significant increase in accelerated principal and interest conversions at the election of the holders and we have continued to offer incentives to the holders of the Notes to facilitate conversions of the outstanding Notes into equity. In addition, at the Fourth Closing, the holders of the Notes will be obligated to purchase at least 50% of the aggregate principal of the Notes they convert, either on a voluntary or installment conversion basis, on and after July 1, 2016, up to an aggregate principal amount of $6.25 million, although no holder will be obligated to purchase more Notes than originally scheduled in the First Amendment. During the third quarter of 2016, $9.8 million of aggregate principal amount of Notes were converted by holders of the Notes into approximately 60.2 million shares. Between October 1, 2016 and November 11, 2016, $3.2 million of aggregate principal amount of Notes were converted by holders of the Notes into approximately 39.7 million shares of the Company’s common stock.

Description of the Notes

The Notes are payable in monthly installments, accrue interest at a rate of 7.0% per annum from the date of issuance and will mature 24 months after the First Closing, unless converted or redeemed earlier. The Notes may be repaid, at the Company’s election, in either cash or shares of the Company’s common stock at a discount to the then-current market price. The Notes are also convertible from time to time, at the election of the holders, into shares of the Company’s common stock at an initial conversion price of $4.35 per share. The conversion price was adjusted to $1.09 per share on January 29, 2016, the 16^th trading day following the Reverse Stock Split, per the terms of the Notes.

The holder of each Note has the right to convert any portion of such Note unless the holder, together with its affiliates, beneficially owns in excess of 4.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to the conversion, as such percentage ownership is determined in accordance with the terms of the Notes. However, any holder may increase or decrease such percentage to any other percentage, but in no event above 9.99%, provided that any increase of such percentage will not be effective until 61 days after providing notice to the Company.

The Company has determined that the conversion feature in the Notes requires bifurcation and liability classification and measurement, at fair value, and requires evaluation at each reporting period. Under Accounting Standards Codification (ASC) 825, Financial Instruments, the FASB provides an alternative to bifurcation and companies may instead elect fair value measurement for the entire instrument, including the debt and conversion feature. The Company has elected the fair value alternative in order to simplify its accounting and reporting of the Notes upon issuance. The fair value of the Warrants is recorded as a discount to the Notes and amortized to interest expense following the effective interest rate method over the term of the Notes.

The First Closing occurred on November 9, 2015. At the First Closing, the Company issued and sold Notes with an aggregate principal amount of $1.5 million, along with Warrants exercisable for 117,520 shares. During the quarter ended September 30, 2016, all remaining principal and interest amounts outstanding under Notes issued at the First Closing were paid off via conversions to common shares.

The Second Closing occurred on January 11, 2016 after the Company received approval of the offering by the Company’s stockholders and the satisfaction of certain customary closing conditions. At the Second Closing, the Company issued and sold Notes with an aggregate principal amount of $11.0 million, along with Warrants exercisable for 861,842 shares. The fair value of the Warrants issued on January 11, 2016 was determined to be $515,000 using a Black-Scholes valuation model and the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 85.90%; (3) weighted average risk –free interest rate of 1.58%; and (4) expected life of 5.0 years.

The Third Closing occurred on May 2, 2016 after the Company entered into the First Amendment and satisfied certain closing conditions. At the Third Closing, the Company issued and sold Notes with an aggregate principal amount of $6.25 million, along with Warrants exercisable for 489,684 shares.

At the Fourth Closing, the Company may be required to issue and sell Notes with an aggregate principal amount of up to $6.25 million, along with Warrants exercisable for 489,682 shares, but only if the holders of the Notes waive the requirement that the Company be in compliance with the Closing Conditions at the Fourth Closing.

The following table summarizes the installment amounts and additional conversions by the holders of the Notes issued at the First Closing through September 30, 2016:


	Principal		Interest		Total		Common Shares
Installment amount at December 31, 2015	$	65,217	$	23,651	$	88,868		56,967
Holder conversions during the quarter ended December 31, 2015		18,261		2,375		20,636		13,228

Balance, December 31, 2015		83,478		26,026		109,504		70,195
Installment amount at February 29, 2016		65,217		23,681		88,898		91,953
Installment amount at March 31, 2016		65,217		14,827		80,044		88,960
Holder conversions during the quarter ended March 31, 2016		104,784		12,762		117,546		106,684

Balance, March 31, 2016		318,696		77,296		395,992		357,792
Installment amount at April 30, 2016		65,217		13,853		79,070		101,764
Installment amount at May 31, 2016		65,217		13,082		78,299		148,467
Installment amount at June 30, 2016		54,217		11,275		65,492		251,320
Holder conversions during the quarter ended June 30, 2016		1,627		174		1,801		2,000

Balance, June 30, 2016		504,974		115,680		620,654		861,343
Installment amount at July 31, 2016		65,217		10,148		75,365		386,492
Installment amount at August 31, 2016		46,957		5,830		52,787		321,505
Holder conversions during the quarter ended September 30, 2016		882,852		78,634		961,486		5,076,930

Balance, September 30, 2016	$	1,500,000	$	210,292	$	1,710,292		6,646,270

The following table summarizes the installment amounts and additional conversions by the holders of the Notes issued at the Second Closing through September 30, 2016:


	Principal		Interest		Total		Common Shares
Installment amount at March 2, 2016	$	404,762	$	149,300	$	554,062			*
Holder conversions during the quarter ended March 31, 2016		987,000		124,050		1,111,050		1,048,167

Balance, March 31, 2016		1,391,762		273,350		1,665,112		1,048,167
Installment amount at April 29, 2016		404,762		149,497		554,259		713,334
Installment amount at May 31, 2016		291,428		86,518		377,946		716,625
Installment amount at June 30, 2016		404,762		82,913		487,675		1,598,908
Holder conversions during the quarter ended June 30, 2016		25,373		2,995		28,368		29,000

Balance, June 30, 2016		2,518,087		595,273		3,113,360		4,106,034
Installment amount at July 31, 2016		213,429		47,457		260,886		1,337,879
Installment amount at August 31, 2016		631,429		116,511		747,940		4,536,725
Installment amount at September 30, 2016		404,762		45,846		450,608		3,618,881
Holder conversions during the quarter ended September 30, 2016		4,868,679		418,847		5,287,526		29,277,719

Balance, September 30, 2016	$	8,636,386	$	1,223,934	$	9,860,320		42,877,238

The following table summarizes the installment amounts and additional conversions by the holders of the Notes issued at the Third Closing through September 30, 2016:


	Principal		Interest		Total		Common Shares
Installment amount at June 30, 2016	$	212,158	$	90,659	$	302,817		1,162,000
Holder conversions during the quarter ended June 30, 2016		—		—		—		—

Balance, June 30, 2016	$	212,158	$	90,659	$	302,817		1,162,000
Installment amount at July 31, 2016		147,368		32,374		179,742		921,757
Cash Payment – July 31, 2016 installment		42,105		6,107		48,212			*
Installment amount at August 31, 2016		336,842		62,059		398,901		2,427,886
Installment amount at September, 2016		263,158		41,822		304,980		2,416,643
Holder conversions during the quarter ended September 30, 2016		1,915,698		175,092		2,090,790		10,869,063

Balance September 30, 2016	$	2,917,329	$	408,113	$	3,325,442		17,797,349

*	Cash payments

Description of the Warrants

Each Warrant is exercisable immediately and for a period of 60 months from the date of the issuance of the Warrant. Upon the completion of the Fourth Closing, the Warrants will entitle the holders of the Warrants to purchase, in aggregate, 1,958,728 shares of the Company’s common stock, subject to certain adjustments. The Warrants were initially exercisable at an exercise price equal to $4.65, subject to adjustment on the eighteen month anniversary of issuance, and certain other adjustments. The exercise price and number of shares of common stock issuable on the exercise of the Warrants is subject to adjustment upon the issuance of any shares of common stock or securities convertible into shares of common stock below the then-existing exercise price, with certain exceptions, and in the event of any stock split, reverse stock split, recapitalization, reorganization or similar transaction. The holder of each Warrant does not have the right to exercise any portion of such Warrant if the holder, together with its affiliates, beneficially owns in excess of 4.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Warrants. However, any holder may increase or decrease such percentage to any other percentage, but in no event above 9.99%, provided that any increase of such percentage will not be effective until 61 days after providing notice to the Company.

The exercise price of the Warrants issued November 9, 2015 was reduced to $1.09 per share on January 29, 2016, the 16^th trading day following the Reverse Stock Split, per the terms of the Warrants. The exercise price of the Warrants issued January 11, 2016 and May 2, 2016 remains $4.65 per share per the terms of the Warrants. All of the Warrants issued with the Notes remain subject to adjustment on the eighteen month anniversary of issuance.

Stock-based Compensation

9 Months Ended

Sep. 30, 2016

Stock-based Compensation

(7) Stock-based Compensation

The fair value method of accounting for share-based payments is applied to all share-based payment awards issued to employees and where appropriate, nonemployees, unless another source of literature applies. When determining the measurement date of a nonemployee’s share-based payment award, the Company measures the stock options at fair value and re-measures such stock options to the current fair value until the performance date has been reached.

Based on the application of these standards, stock-based compensation expense for stock-based awards under the Company’s Amended and Restated 2003 Stock Incentive Plan (the Plan) and inducement grants for the three and nine months ended September 30, 2016 and 2015 was allocated to operating expenses and employees and nonemployees as follows:


	Three months ended September 30,				Nine months ended September 30,
	2016		2015		2016		2015
Selling, general and administrative	$	310,133	$	1,107,526	$	1,731,768	$	3,349,417
Research and development		45,203		329,431		470,181		1,008,325

Total	$	355,336	$	1,436,957	$	2,201,949	$	4,357,742


	Three months ended September 30,					Nine months ended September 30,
	2016		2015			2016		2015
Employees	$	355,225	$	1,452,709		$	2,198,414	$	4,392,741
Nonemployees	$	111		(15,752	)		3,535		(34,999	)

Total	$	355,336	$	1,436,957		$	2,201,949	$	4,357,742

On June 27, 2016 the Company completed an option exchange offer to its employees whereby certain outstanding options to purchase shares of the Company’s common stock were tendered by employees in exchange for new options with the exercise price to be set at the then current market price of the Company’s common stock. Options to purchase 449,706 shares of the Company’s common stock, which included all the options eligible for exchange, were tendered by employees and cancelled by the Company. On the same date, options to purchase 75,819 shares of the Company’s common stock were issued with an exercise price of $0.3325 per share, which was the Company’s closing stock price on June 27, 2016. Because the fair value of the tendered options immediately before the exchange approximated the fair value of the new options granted, no additional compensation expense was recognized.

As of September 30, 2016 there was approximately $3.5 million of total unrecognized compensation costs, net of estimated forfeitures, related to employee unvested stock option awards, which are expected to be recognized over a weighted-average period of 2.37 years.

The estimated grant-date fair values of the stock options were calculated using the Black-Scholes valuation model, based on the following assumptions for the three and nine months ended September 30, 2016 and 2015:


	Employees						Employees
	Three months ended September 30,						Nine months ended September 30,
	2016			2015			2016			2015
Risk-free interest rates		N/A			1.65%-1.67	%		0.87%-1.64	%		1.49%-1.80	%
Expected life		N/A			6.00-6.25 years			4.00-6.25 years			5.50-6.25 years
Expected dividends		N/A			0	%		0	%		0	%
Expected volatility		N/A			110.72%-111.61	%		88.43%-96.10	%		83.36%-111.77	%

	Nonemployees						Nonemployees
	Three months ended September 30,						Nine months ended September 30,
	2016			2015			2016			2015
Risk-free interest rates		1.03	%		1.34%-1.79	%		0.89%-1.11	%		0.02%-2.10	%
Expected life		4.00 years			4.89-8.01 years			4.00-4.39 years			0.08-8.51 years
Expected dividends		0	%		0	%		0	%		0	%
Expected volatility		96.64	%		83.98%-114.89	%		92.41%-96.64	%		22.42%-132.01	%

Option activity under the Plan for the nine months ended September 30, 2016 was as follows:


				Outstanding Options
	Shares Available For Grant			Number of Shares			Weighted- Average Exercise Price
Balance, December 31, 2015		296,579			1,018,752		$	32.83
Shares reserved		—			—			—
Options granted		(152,152	)		152,152			0.65
Options exercised		—			—			—
Options cancelled		652,653			(652,653	)		31.40

Balance, September 30, 2016		797,080			518,251			25.55

In addition to the stock options granted pursuant to the Plan, the Company has also granted inducement stock options in connection with the appointments of (i) Dan Gladney to the position of President and Chief Executive Officer on October 28, 2015, (ii) Nick Ansari to the position of Senior Vice President (SVP) of Sales on January 6, 2016, (iii) Peter DeLange to the position of SVP of Operations and Business Development on January 18, 2016 and (iv) Paul Hickey to the position of SVP of Marketing and Reimbursement on January 18, 2016. Mr. Gladney was granted an option to purchase 516,666 shares of the Company’s common stock as an inducement grant, with an exercise price of $3.75 per share, the closing price of the Company’s common stock on October 28, 2015. Mr. Delange was granted an option to purchase 166,667 shares of the Company’s common stock as an inducement grant, with an exercise price of $1.38 per share, the closing price of the Company’s common stock on January 18, 2016. Mr. Ansari was granted an option to purchase 106,667 shares of the Company’s common stock as an inducement grant, with an exercise price of $1.31 per share, the closing price of the Company’s common stock on January 19, 2016. Mr. Hickey was granted an option to purchase 106,667 shares of the Company’s common stock as an inducement grant, with an exercise price of $1.32 per share, the closing price of the Company’s common stock on January 22, 2016. Each of the inducement grants will vest as follows: 25% of the shares will vest as of one year from the date of the officer’s employment agreement, and the remaining 75% of the shares will then vest in equal 2.0833% installments each month thereafter for 36 months. The inducement options were not eligible for the option exchange program.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

Stock Sales

9 Months Ended

Sep. 30, 2016

Stock Sales

(8) Stock Sales

Sales Agreement—July 2015

On July 8, 2015, the Company closed a public offering, where it sold 2,133,333 units at an aggregate price of $7.50 per unit, for gross proceeds of $16.0 million before deducting estimated offering expenses of approximately $1.4 million, of which $532,000 was assigned to the warrants issued with each unit sold and was recognized immediately as interest expense in the condensed consolidated statements of operations as the warrants are exercisable upon issuance. Each unit consisted of: (A)(i) one share of common stock or (ii) one pre-funded Series C warrant to purchase one share of common stock at an exercise price equal to $7.50 per share (Series C Warrant); and (B) one Series A warrant to purchase one share of common stock at an exercise price initially equal to $9.00 per share (Series A Warrant). Each purchaser of a unit could elect to receive a Series C Warrant in lieu of a share of common stock. No Series C Warrants were issued.

The Series A Warrants are exercisable for a period of 42 months from the closing date of the public offering. The exercise price and number of shares of common stock issuable on the exercise of the Series A Warrants are subject to adjustment upon the issuance of any shares of common stock or securities convertible into shares of common stock below the then-existing exercise price, with certain exceptions, and in the event of any stock split, reverse stock split, recapitalization, reorganization or similar transaction. The holder of the Series A Warrant does not have the right to exercise any portion of the Series A Warrant if the holder, together with its affiliates, would, subject to certain limited exceptions, beneficially own in excess of 9.99% of the Company’s common stock outstanding immediately after the exercise or 4.99% as may be elected by the purchaser.

The exercise price of the Series A Warrants issued July 8, 2015 was reduced to $2.40 per share on November 9, 2015 as a result of the issuance of the Notes and was further reduced to $1.50 per share on December 31, 2015, $0.97 per share on January 29, 2016, and $0.88 on March 30, 2016, $0.26 on June 30, 2016, $0.19 on August 1, 2016, $0.13 on September 30, 2016 and $0.08 on October 31, 2016 as a result of conversions of principal and interest amounts outstanding under the Notes into shares of our common stock.

Sales Agreement—June 2014

On June 13, 2014, the Company entered into a sales agreement with Cowen and Company, LLC (Cowen) to sell shares of the Company’s common stock having aggregate gross sales proceeds of up to $25.0 million, from time to time, through an “at-the-market” equity offering program under which Cowen will act as the Company’s sales agent (the Cowen ATM). The Company will determine, at its sole discretion, the timing and number of shares to be sold under the Cowen ATM. The Company will pay Cowen a commission for its services in acting as agent in the sale of common stock equal to 3.0% of the gross sales price per share of all shares sold through it as agent under the sales agreement. As of December 31, 2015, the Company had sold 367,903 shares under the Cowen ATM at a weighted-average selling price of $20.60 per share for gross proceeds of $7.6 million before deducting offering expenses. There have been no shares sold under the Cowen ATM subsequent to December 31, 2015 through November 11 , 2016. The Company was restricted from issuing shares under the Cowen ATM until November 9, 2016 per the terms of the Purchase Agreement.

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2016

Description of Business

Description of Business

Risks and Uncertainties

Risks and Uncertainties

Basis of Presentation

Basis of Presentation

Use of Estimates

Use of Estimates

Principles of Consolidation

Principles of Consolidation

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Common Stock Warrant Liability

Common Stock Warrant Liability

Cash and Cash Equivalents

Cash and Cash Equivalents

Short-Term Investments

Short-Term Investments

Inventory

Inventory

The Company accounts for inventory at the lower of cost or market and records any long-term inventory as other assets in the condensed consolidated balance sheets.

Property and Equipment, Net

Property and Equipment, Net

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

Income Taxes

Income Taxes

Medical Device Excise Tax

Medical Device Excise Tax

Comprehensive Loss

Comprehensive Loss

Revenue Recognition

Revenue Recognition

Research and Development Expenses

Research and Development Expenses

Net Loss Per Share

Net Loss Per Share

The following table sets forth the computation of basic and diluted net loss per share for the three and nine months ended September 30, 2016 and 2015:


	Three months ended September 30,						Nine months ended September 30,
	2016			2015			2016			2015
Numerator:
Net loss	$	(6,522,463	)	$	(4,150,670	)	$	(18,926,390	)	$	(18,728,455	)

Denominator for basic and diluted net loss per share:
Weighted-average common shares outstanding		38,781,980			6,931,306			19,162,561			5,587,847

Net loss per share—basic and diluted	$	(0.17	)	$	(0.60	)	$	(0.99	)	$	(3.35	)


	September 30,
	2016		2015
Stock options outstanding		1,414,918		1,030,033
Warrants to purchase common stock		3,953,413		3,746,647

Recently Issued or Adopted Accounting Standards

Recently Issued or Adopted Accounting Standards

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2016

Computation of Basic and Diluted Net Loss per Share

The following table sets forth the computation of basic and diluted net loss per share for the three and nine months ended September 30, 2016 and 2015:


	Three months ended September 30,						Nine months ended September 30,
	2016			2015			2016			2015
Numerator:
Net loss	$	(6,522,463	)	$	(4,150,670	)	$	(18,926,390	)	$	(18,728,455	)

Denominator for basic and diluted net loss per share:
Weighted-average common shares outstanding		38,781,980			6,931,306			19,162,561			5,587,847

Net loss per share—basic and diluted	$	(0.17	)	$	(0.60	)	$	(0.99	)	$	(3.35	)

Antidilutive Securities


	September 30,
	2016		2015
Stock options outstanding		1,414,918		1,030,033
Warrants to purchase common stock		3,953,413		3,746,647

Short-term Investments and Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2016

Summary of Fair Value Measurements of Senior Amortizing Convertible Notes and Common Stock Warrants

The following table summarizes fair value measurements of the Notes and the common stock warrants issued in 2015 and during the nine months ended September 30, 2016 by level at September 30, 2016:


	Level 1	Level 2		Level 3		Total
Senior amortizing convertible notes				$	5,676,000	$	5,676,000
Common stock warrants		$	212,915				212,915

Total		$	212,915	$	5,676,000	$	5,888,915

Warrant Liability

Schedule Of Assumption used to Calculate Fair Value

The fair value was calculated using the following assumptions:


	July 2015 Warrants						November 2015 Warrants
	September 30, 2016			December 31, 2015			September 30, 2015			December 31, 2015
Risk-free interest rates		0.88	%		1.31	%		1.14	%		1.76	%
Expected life		27 months			36 months			49 months			58 months
Expected dividends		0	%		0	%		0	%		0	%
Expected volatility		97.89	%		97.94	%		96.40	%		86.27	%

	January 2016 Warrants						May 2016 Warrants
	September 30, 2016			January 11, 2016			September 30, 2016			May 2, 2016
Risk-free interest rates		1.14	%		1.58	%		1.14	%		1.32	%
Expected life		51 months			60 months			55 months			60 months
Expected dividends		0	%		0	%		0	%		0	%
Expected volatility		96.12	%		85.90	%		94.95	%		89.28	%

Senior Amortizing Convertible Notes

Schedule Of Assumption used to Calculate Fair Value

The fair values were calculated using a Binomial Lattice model and the following assumptions:


	November 2015 Notes					January 2016 Notes
	September 30, 2016		December 31, 2015			September 30, 2016			January 11, 2016
Risk-free interest rates		N/A		1.11	%		0.65	%		1.01	%
Expected life		N/A		1.86 years			1.11 years			1.83 years
Expected dividends		N/A		0	%		0	%		0	%
Expected volatility		N/A		57.5	%		70.0	%		60.0	%
Fair value per share of common stock		N/A	$	1.95		$	0.14		$	1.33


	May 2016 Notes
	September 30, 2016			May 2, 2016
Risk-free interest rates		0.65	%		0.69	%
Expected life		1.11 years			1.52 years
Expected dividends		0	%		0	%
Expected volatility		70.0	%		65.0	%
Fair value per share of common stock	$	0.14		$	0.80

Inventory (Tables)

9 Months Ended

Sep. 30, 2016

Current Inventory

Current inventory consists of the following as of:


	September 30, 2016		December 31, 2015
Raw materials	$	686,629	$	576,898
Work-in-process		1,431,056		1,066,345
Finished goods		16,176		43,081

Inventory	$	2,133,861	$	1,686,324

Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2016

Future Minimum Payments under Lease

At September 30, 2016, future minimum payments under the lease are as follows:


Year ending December 31:
Remaining three months in 2016	$	58,905
2017		235,620
2018		176,715

	$	471,240

Senior Amortizing Convertible Notes (Tables)

9 Months Ended

Sep. 30, 2016

Summary of Installment Amounts and Additional Conversions

The following table summarizes the installment amounts and additional conversions by the holders of the Notes issued at the First Closing through September 30, 2016:


	Principal		Interest		Total		Common Shares
Installment amount at December 31, 2015	$	65,217	$	23,651	$	88,868		56,967
Holder conversions during the quarter ended December 31, 2015		18,261		2,375		20,636		13,228

Balance, December 31, 2015		83,478		26,026		109,504		70,195
Installment amount at February 29, 2016		65,217		23,681		88,898		91,953
Installment amount at March 31, 2016		65,217		14,827		80,044		88,960
Holder conversions during the quarter ended March 31, 2016		104,784		12,762		117,546		106,684

Balance, March 31, 2016		318,696		77,296		395,992		357,792
Installment amount at April 30, 2016		65,217		13,853		79,070		101,764
Installment amount at May 31, 2016		65,217		13,082		78,299		148,467
Installment amount at June 30, 2016		54,217		11,275		65,492		251,320
Holder conversions during the quarter ended June 30, 2016		1,627		174		1,801		2,000

Balance, June 30, 2016		504,974		115,680		620,654		861,343
Installment amount at July 31, 2016		65,217		10,148		75,365		386,492
Installment amount at August 31, 2016		46,957		5,830		52,787		321,505
Holder conversions during the quarter ended September 30, 2016		882,852		78,634		961,486		5,076,930

Balance, September 30, 2016	$	1,500,000	$	210,292	$	1,710,292		6,646,270

The following table summarizes the installment amounts and additional conversions by the holders of the Notes issued at the Second Closing through September 30, 2016:


	Principal		Interest		Total		Common Shares
Installment amount at March 2, 2016	$	404,762	$	149,300	$	554,062			*
Holder conversions during the quarter ended March 31, 2016		987,000		124,050		1,111,050		1,048,167

Balance, March 31, 2016		1,391,762		273,350		1,665,112		1,048,167
Installment amount at April 29, 2016		404,762		149,497		554,259		713,334
Installment amount at May 31, 2016		291,428		86,518		377,946		716,625
Installment amount at June 30, 2016		404,762		82,913		487,675		1,598,908
Holder conversions during the quarter ended June 30, 2016		25,373		2,995		28,368		29,000

Balance, June 30, 2016		2,518,087		595,273		3,113,360		4,106,034
Installment amount at July 31, 2016		213,429		47,457		260,886		1,337,879
Installment amount at August 31, 2016		631,429		116,511		747,940		4,536,725
Installment amount at September 30, 2016		404,762		45,846		450,608		3,618,881
Holder conversions during the quarter ended September 30, 2016		4,868,679		418,847		5,287,526		29,277,719

Balance, September 30, 2016	$	8,636,386	$	1,223,934	$	9,860,320		42,877,238

The following table summarizes the installment amounts and additional conversions by the holders of the Notes issued at the Third Closing through September 30, 2016:


	Principal		Interest		Total		Common Shares
Installment amount at June 30, 2016	$	212,158	$	90,659	$	302,817		1,162,000
Holder conversions during the quarter ended June 30, 2016		—		—		—		—

Balance, June 30, 2016	$	212,158	$	90,659	$	302,817		1,162,000
Installment amount at July 31, 2016		147,368		32,374		179,742		921,757
Cash Payment – July 31, 2016 installment		42,105		6,107		48,212			*
Installment amount at August 31, 2016		336,842		62,059		398,901		2,427,886
Installment amount at September, 2016		263,158		41,822		304,980		2,416,643
Holder conversions during the quarter ended September 30, 2016		1,915,698		175,092		2,090,790		10,869,063

Balance September 30, 2016	$	2,917,329	$	408,113	$	3,325,442		17,797,349

*	Cash payments

Stock-based Compensation (Tables)

9 Months Ended

Sep. 30, 2016

Summary of Operating Expenses and Employee and Nonemployees


	Three months ended September 30,				Nine months ended September 30,
	2016		2015		2016		2015
Selling, general and administrative	$	310,133	$	1,107,526	$	1,731,768	$	3,349,417
Research and development		45,203		329,431		470,181		1,008,325

Total	$	355,336	$	1,436,957	$	2,201,949	$	4,357,742


	Three months ended September 30,					Nine months ended September 30,
	2016		2015			2016		2015
Employees	$	355,225	$	1,452,709		$	2,198,414	$	4,392,741
Nonemployees	$	111		(15,752	)		3,535		(34,999	)

Total	$	355,336	$	1,436,957		$	2,201,949	$	4,357,742

Stock Option Valuation Assumptions


	Employees						Employees
	Three months ended September 30,						Nine months ended September 30,
	2016			2015			2016			2015
Risk-free interest rates		N/A			1.65%-1.67	%		0.87%-1.64	%		1.49%-1.80	%
Expected life		N/A			6.00-6.25 years			4.00-6.25 years			5.50-6.25 years
Expected dividends		N/A			0	%		0	%		0	%
Expected volatility		N/A			110.72%-111.61	%		88.43%-96.10	%		83.36%-111.77	%

	Nonemployees						Nonemployees
	Three months ended September 30,						Nine months ended September 30,
	2016			2015			2016			2015
Risk-free interest rates		1.03	%		1.34%-1.79	%		0.89%-1.11	%		0.02%-2.10	%
Expected life		4.00 years			4.89-8.01 years			4.00-4.39 years			0.08-8.51 years
Expected dividends		0	%		0	%		0	%		0	%
Expected volatility		96.64	%		83.98%-114.89	%		92.41%-96.64	%		22.42%-132.01	%

Summary of Stock Option Activity

Option activity under the Plan for the nine months ended September 30, 2016 was as follows:


				Outstanding Options
	Shares Available For Grant			Number of Shares			Weighted- Average Exercise Price
Balance, December 31, 2015		296,579			1,018,752		$	32.83
Shares reserved		—			—			—
Options granted		(152,152	)		152,152			0.65
Options exercised		—			—			—
Options cancelled		652,653			(652,653	)		31.40

Balance, September 30, 2016		797,080			518,251			25.55

Summary of Significant Accounting Policies - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2016 USD ($) shares	Jan. 06, 2016 shares	Dec. 31, 2015 shares	Sep. 30, 2015 USD ($)
Schedule Of Significant Accounting Policies [Line Items]
Common stock, reverse split ratio		0.0667
Common stock authorized for issuance \| shares	150,000,000	150,000,000	13,333,333
Cash equivalents maturity period	90 days
Excise tax rate on medical devices	2.30%
Provision for returns \| $	$ 0			$ 0
Minimum
Schedule Of Significant Accounting Policies [Line Items]
Short term investment maturity period	3 months
Maximum
Schedule Of Significant Accounting Policies [Line Items]
Short term investment maturity period	1 year
Furniture and Fixtures \| Minimum
Schedule Of Significant Accounting Policies [Line Items]
Property and equipment estimated useful lives	5 years
Furniture and Fixtures \| Maximum
Schedule Of Significant Accounting Policies [Line Items]
Property and equipment estimated useful lives	7 years
Computer hardware and software \| Minimum
Schedule Of Significant Accounting Policies [Line Items]
Property and equipment estimated useful lives	3 years
Computer hardware and software \| Maximum
Schedule Of Significant Accounting Policies [Line Items]
Property and equipment estimated useful lives	5 years

Computation of Basic and Diluted Net Loss Per Share (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Numerator:
Net loss	$ (6,522,463)	$ (4,150,670)	$ (18,926,390)	$ (18,728,455)
Denominator for basic and diluted net loss per share:
Weighted-average common shares outstanding	38,781,980	6,931,306	19,162,561	5,587,847
Net loss per share-basic and diluted	$ (0.17)	$ (0.60)	$ (0.99)	$ (3.35)

Potential Shares of Common Stock Not Included in Calculation of Diluted Net Loss per Share (Detail) - shares	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Stock Option Outstanding
Anti-dilutive Securities
Anti-dilutive as of end of each period	1,414,918	1,030,033
Warrants to purchase common stock
Anti-dilutive Securities
Anti-dilutive as of end of each period	3,953,413	3,746,647

Liquidity and Management's Plans - Additional Information (Detail) - USD ($)	1 Months Ended
	May 31, 2016	Dec. 01, 2016	Sep. 30, 2016	May 02, 2016	Jan. 11, 2016	Dec. 31, 2015	Nov. 09, 2015	Nov. 04, 2015	Sep. 30, 2015	Jul. 08, 2015	Dec. 31, 2014
Liquidity and Managements Plans [Line Items]
Cash and cash equivalents			$ 6,841,547			$ 7,927,240			$ 12,260,989		$ 11,619,167
Shares issued, price per unit										$ 7.50
Common stock value			$ 744,145			$ 71,638
Nasdaq Stock Market
Liquidity and Managements Plans [Line Items]
Minimum stockholders' Equity requirement	$ 2,500,000
Minimum bid price requirement	$ 1.00
Senior Amortizing Convertible Note
Liquidity and Managements Plans [Line Items]
Senior amortizing convertible notes issued								$ 25,000,000
Senior Amortizing Convertible Note \| First closing
Liquidity and Managements Plans [Line Items]
Senior amortizing convertible notes issued							$ 1,500,000
Senior Amortizing Convertible Note \| Second closing
Liquidity and Managements Plans [Line Items]
Senior amortizing convertible notes issued					$ 11,000,000
Senior Amortizing Convertible Note \| Third closing \| Amendment
Liquidity and Managements Plans [Line Items]
Senior amortizing convertible notes issued				$ 6,250,000
Senior Amortizing Convertible Note \| Fourth closing \| Minimum
Liquidity and Managements Plans [Line Items]
Shares issued, price per unit			$ 0.20
Common stock value			$ 100,000
Scenario, Forecast \| Senior Amortizing Convertible Note \| Fourth closing \| Amendment
Liquidity and Managements Plans [Line Items]
Senior amortizing convertible notes issued		$ 6,250,000

Short - term Investment and Fair Value Measurements - Additional Information (Detail) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2016	May 02, 2016	Jan. 11, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Senior amortizing convertible notes principal and interest converted into shares of common stock		$ 3,200,000
Change in value of convertible notes payable	$ (909,030)	(200,004)
Fair value of outstanding convertible notes	5,676,000	5,676,000
First closing
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of outstanding convertible notes					$ 1,300,000
Second closing
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of outstanding convertible notes	2,400,000	2,400,000		$ 9,900,000
Third closing
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of outstanding convertible notes	3,200,000	3,200,000	$ 6,000,000
Common Stock
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants	212,915	212,915
Warrants Issued July 8, 2015 \| Common Stock
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants	172,981	172,981			2,759,583
Warrants Issued November 9, 2015 \| Common Stock
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants	14,488	14,488			$ 118,234
Warrants Issued January 11, 2016 \| Common Stock
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants	15,610	15,610		$ 515,157
Warrants Issued May 2, 2016 \| Common Stock
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants	$ 9,836	$ 9,836	$ 150,195

Series A Warrants Fair Value Calculated Using Black-Scholes Valuation Model (Detail)			9 Months Ended	12 Months Ended
	May 02, 2016	Jan. 11, 2016	Sep. 30, 2016	Dec. 31, 2015
Warrants Issued July 8, 2015
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rates			0.88%	1.31%
Expected life			27 months	36 months
Expected dividends			0.00%	0.00%
Expected volatility			97.89%	97.94%
Warrants Issued November 9, 2015
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rates			1.14%	1.76%
Expected life			49 months	58 months
Expected dividends			0.00%	0.00%
Expected volatility			96.40%	86.27%
Warrants Issued January 11, 2016
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rates		1.58%	1.14%
Expected life		60 months	51 months
Expected dividends		0.00%	0.00%
Expected volatility		85.90%	96.12%
Warrants Issued May 2, 2016
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rates	1.32%		1.14%
Expected life	60 months		55 months
Expected dividends	0.00%		0.00%
Expected volatility	89.28%		94.95%

Summary of Fair Value Measurements of Senior Amortizing Convertible Notes and Common Stock Warrants (Detail)	Sep. 30, 2016 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Senior amortizing convertible notes	$ 5,676,000
Total	5,888,915
Common Stock
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants	212,915
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	212,915
Level 2 \| Common Stock
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants	212,915
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Senior amortizing convertible notes	5,676,000
Total	$ 5,676,000

Schedule of Fair Value Assumption Calculated Using Binomial Lattice Model (Detail) - $ / shares			9 Months Ended	12 Months Ended
	May 02, 2016	Jan. 11, 2016	Sep. 30, 2016	Dec. 31, 2015
November Twenty Fifteen Notes
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rates				1.11%
Expected life				1 year 10 months 10 days
Expected dividends				0.00%
Expected volatility				57.50%
Fair value per share of common stock				$ 1.95
January Twenty Sixteen Notes
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rates		1.01%	0.65%
Expected life		1 year 9 months 29 days	1 year 1 month 10 days
Expected dividends		0.00%	0.00%
Expected volatility		60.00%	70.00%
Fair value per share of common stock		$ 1.33	$ 0.14
May Twenty Sixteen Notes
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rates	0.69%		0.65%
Expected life	1 year 6 months 7 days		1 year 1 month 10 days
Expected dividends	0.00%		0.00%
Expected volatility	65.00%		70.00%
Fair value per share of common stock	$ 0.80		$ 0.14

Inventory - Additional Information (Detail) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Inventory [Line Items]
Long-term inventory	$ 686,000	$ 519,000

Current Inventory (Detail) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Inventory [Line Items]
Raw materials	$ 686,629	$ 576,898
Work-in-process	1,431,056	1,066,345
Finished goods	16,176	43,081
Inventory	$ 2,133,861	$ 1,686,324

Commitments and Contingencies - Additional Information (Detail) - USD ($)		3 Months Ended		9 Months Ended
	Aug. 25, 2015	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Loss Contingencies [Line Items]
Operating lease agreement expiration date	Sep. 30, 2018
Operating lease agreement term	3 years
Total rent expense		$ 58,905	$ 67,718	$ 176,175	$ 203,154
Number of months that require patients to be followed out in clinical trials				60 months
Minimum
Loss Contingencies [Line Items]
Operating lease, monthly base rent	$ 18,925
Maximum
Loss Contingencies [Line Items]
Operating lease, monthly base rent	$ 20,345

Future Minimum Lease Payment (Detail)	Sep. 30, 2016 USD ($)
Leases Future Minimum Payments [Line Items]
Remaining three months in 2016	$ 58,905
2017	235,620
2018	176,715
Operating Leases, Future Minimum Payments Due, Total	$ 471,240

Senior Amortizing Convertible Notes - Additional Information (Detail) - USD ($)						1 Months Ended	3 Months Ended			9 Months Ended	12 Months Ended
	Dec. 01, 2016	May 02, 2016	Jan. 11, 2016	Nov. 09, 2015	Nov. 04, 2015	Nov. 11, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Sep. 30, 2016	Dec. 31, 2015	Jan. 29, 2016
Debt Instrument [Line Items]
Convertible notes, per share price				$ 4.35	$ 4.35							$ 1.09
Exercise price		$ 4.65	$ 4.65	$ 4.65								$ 1.09
Convertible notes, interest rate				7.00%
Aggregate principal amount converted in to shares										$ 3,200,000
Convertible notes, maturity period				24 months
Issued warrant				1,958,728
Warrants issued, exercisable time period				60 months
Third closing
Debt Instrument [Line Items]
Share issued up on conversion							17,797,349	1,162,000
Second closing
Debt Instrument [Line Items]
Share issued up on conversion							42,877,238	4,106,034	1,048,167
First closing
Debt Instrument [Line Items]
Share issued up on conversion							6,646,270	861,343	357,792		70,195
Minimum
Debt Instrument [Line Items]
Common stock ownership percentage required to exercise warrants				4.99%
Period available for the percentage to be effective				61 days
Maximum
Debt Instrument [Line Items]
Common stock ownership percentage required to exercise warrants				9.99%
Senior Amortizing Convertible Note
Debt Instrument [Line Items]
Senior amortizing convertible notes to be issue					$ 25,000,000
Exercise price					$ 4.65
Proceeds from issuance of debt instrument including warrants					$ 12,500,000
Convertible notes, interest rate					7.00%
Senior convertible notes, maturity year					2017
Aggregate principal amount converted in to shares							$ 9,800,000
Share issued up on conversion							60,200,000
Senior Amortizing Convertible Note \| Subsequent Event
Debt Instrument [Line Items]
Aggregate principal amount converted in to shares						$ 3,200,000
Share issued up on conversion						39,700,000
Senior Amortizing Convertible Note \| Fourth closing \| Amendment \| Scenario, Forecast
Debt Instrument [Line Items]
Senior amortizing convertible notes to be issue	$ 6,250,000
Proceeds from issuance of debt instrument including warrants	$ 6,250,000
Issued warrant	489,682
Senior Amortizing Convertible Note \| Third closing \| Amendment
Debt Instrument [Line Items]
Senior amortizing convertible notes to be issue		$ 6,250,000
Proceeds from issuance of debt instrument including warrants		$ 6,250,000
Issued warrant		489,684
Senior Amortizing Convertible Note \| Second closing
Debt Instrument [Line Items]
Senior amortizing convertible notes to be issue			$ 11,000,000
Issued warrant			861,842
Fair value of warrants			$ 515,000
Expected dividends			0.00%
Expected volatility			85.90%
Risk-free interest rates			1.58%
Expected life			5 years
Senior Amortizing Convertible Note \| First closing
Debt Instrument [Line Items]
Senior amortizing convertible notes to be issue				$ 1,500,000
Issued warrant				117,520

Summary of Installment Amounts and Additional Conversions (Detail) - USD ($)

3 Months Ended

9 Months Ended

12 Months Ended

Sep. 30, 2016

Jun. 30, 2016

Mar. 31, 2016

Sep. 30, 2016

Dec. 31, 2015

Stock Options - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions		9 Months Ended
	Jun. 27, 2016	Sep. 30, 2016
Schedule Of Stock Options [Line Items]
Common stock tendered by employees and canceled by the company	449,706
Common stock issued to employees	75,819
Exercise price of option to purchase	$ 0.3325
Total unrecognized compensation costs related to non-vested stock options		$ 3.5
Total unrecognized compensation costs related to non-vested stock options, weighted-average period of recognition		2 years 4 months 13 days
President and Chief Executive Officer
Schedule Of Stock Options [Line Items]
Award granted, shares		516,666
Award granted, exercise price per share		$ 3.75
Award granted, vesting installment percentage		2.0833%
Award vesting period		36 months
Senior Vice President of Operations and Business Development Mr. Delange
Schedule Of Stock Options [Line Items]
Award granted, shares		166,667
Award granted, exercise price per share		$ 1.38
Senior Vice President of Sales
Schedule Of Stock Options [Line Items]
Award granted, shares		106,667
Award granted, exercise price per share		$ 1.31
Senior Vice President of Marketing and Reimbursement
Schedule Of Stock Options [Line Items]
Award granted, shares		106,667
Award granted, exercise price per share		$ 1.32
Vest as of one year from the date of his employment agreement \| President and Chief Executive Officer
Schedule Of Stock Options [Line Items]
Award granted, vesting percentage		25.00%
Vest in equal 2.0833% installments each month thereafter over the following 36 months \| President and Chief Executive Officer
Schedule Of Stock Options [Line Items]
Award granted, vesting percentage		75.00%

Summary of Stock Option Activity (Detail) - $ / shares		9 Months Ended
Summary of Stock Option Activity (Detail) - $ / shares	Jun. 27, 2016	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Options, Number of Shares, Options cancelled	(449,706)
Stock Incentive Plan 2003
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Available For Grant, Beginning Balance		296,579
Shares Available For Grant, Shares reserved		0
Shares Available For Grant, Options granted		(152,152)
Shares Available For Grant, Options exercised		0
Shares Available For Grant, Options cancelled		652,653
Shares Available For Grant, Ending Balance		797,080
Outstanding Options, Number of Shares, Beginning Balance		1,018,752
Outstanding Options, Number of Shares, Shares reserved		0
Outstanding Options, Number of Shares, Options granted		152,152
Outstanding Options, Number of Shares, Options exercised		0
Outstanding Options, Number of Shares, Options cancelled		(652,653)
Outstanding Options, Number of Shares, Ending Balance		518,251
Outstanding Options, Weighted-Average Exercise Price, Beginning Balance		$ 32.83
Outstanding Options, Weighted-Average Exercise Price, Shares reserved		0
Outstanding Options, Weighted-Average Exercise Price, Options granted		0.65
Outstanding Options, Weighted-Average Exercise Price, Options exercised		0
Outstanding Options, Weighted-Average Exercise Price, Options cancelled		31.40
Outstanding Options, Weighted-Average Exercise Price, Ending Balance		$ 25.55

Stock Sales - Additional Information (Detail) - USD ($)			12 Months Ended
Stock Sales - Additional Information (Detail) - USD ($)	Jul. 08, 2015	Jun. 13, 2014	Dec. 31, 2015	Oct. 31, 2016	Sep. 30, 2016	Aug. 01, 2016	Jun. 30, 2016	May 02, 2016	Mar. 30, 2016	Jan. 29, 2016	Jan. 11, 2016	Nov. 09, 2015
Class of Stock [Line Items]
Public offering selling units	2,133,333
Shares issued, price per unit	$ 7.50
Gross proceeds before deducting estimate offering expenses	$ 16,000,000
Offering costs	$ 1,400,000
Exercise price								$ 4.65		$ 1.09	$ 4.65	$ 4.65
Beneficial ownership percentage	9.99%
Cowen and Company LLC
Class of Stock [Line Items]
Gross proceeds before deducting estimate offering expenses			$ 7,600,000
Commission or discount percentage on issue of shares		3.00%
Number of shares sold			367,903
Warrants to purchase common stock
Class of Stock [Line Items]
Offering costs	$ 532,000
Series C Warrants
Class of Stock [Line Items]
Exercise price	$ 7.50
Warrant issued	0
Series A Warrants
Class of Stock [Line Items]
Exercise price	$ 9.00		$ 1.50		$ 0.13	$ 0.19	$ 0.26		$ 0.88	$ 0.97		$ 2.40
Warrants exercisable period	42 months
Series A Warrants \| Subsequent Event
Class of Stock [Line Items]
Exercise price				$ 0.08
Minimum
Class of Stock [Line Items]
Beneficial ownership percentage	4.99%
Maximum \| Cowen and Company LLC
Class of Stock [Line Items]
Gross proceeds before deducting estimate offering expenses		$ 25,000,000
Weighted Average \| Cowen and Company LLC
Class of Stock [Line Items]
Sale of stock, price per share			$ 20.60